• Explore /
  • Poster
  • / Dose-intensified rechallenge with temozolomide: One week on/one week off versus 3 weeks on/one week off in patients with progressive or recurrent glioblastoma (DIRECTOR).

Dose-intensified rechallenge with temozolomide: One week on/one week off versus 3 weeks on/one week off in patients with progressive or recurrent glioblastoma (DIRECTOR).

Abstract Poster

Authors

Ghazaleh Tabatabai

Ghazaleh Tabatabai

Department of Neurology, University Hospital Zurich, Zurich, Switzerland

Ghazaleh Tabatabai , Wolfgang Wick , Guido Reifenberger , Joachim Peter Steinbach , Oliver Schnell , Peter Hau , Ulrich Herrlinger , Michael Sabel , Ralf Ketter , Uwe S. Schlegel , Christine Marosi , Roland Goldbrunner , Krisztian Homicsko , Guido Nikkhah , Josef Pichler , Peter Vajkoczy , Juergen Meixensberger , Michael Weller

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Central Nervous System Tumors

Clinical Trial Registration Number

NCT00941460

Citation

J Clin Oncol 31, 2013 (suppl; abstr TPS2103)

DOI

10.1200/jco.2013.31.15_suppl.tps2103

Abstract #

TPS2103

Poster Bd #

9C

Abstract Disclosures

Similar Posters

First Author: Michael Weller

First Author: Dorota Goplen

First Author: Lindsay J Lipinski

First Author: Kerrie Leanne McDonald